Two leaders in lipid nanoparticle (LNP) development have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-vira...
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clin...
Expanded Strategic Partnership Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers Thermo Fisher Scien...
Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has approved HERNEXEOS® (zongertinib tablets)...
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KA...
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Universitätsmedizin Göttingen (UMG Göttinge...
Foresight Diagnostics ("Foresight") announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Sy...
AmeriWater, a leading provider of advanced water purification systems for healthcare, is pleased to announce it has signed an agreement with Vizient®...
-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...
Scenic Biotech, a pioneer in modifier therapies for severe diseases, announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDA...
Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, entered a non-exclus...
When it comes to the field of computational biology, rProteins and bioinformatics fit together almost like a lock and key. Recombinant protein techn...
Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new co...
HUTCHMED (China) Limited announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRI...
© 2025 Biopharma Boardroom. All Rights Reserved.
